Patient age | HIV viral load (copies/ml) | CD4+ (cell/ml) | Pap cytology1 | HPV type2 |
---|---|---|---|---|
Group I3 | ||||
45 | < 50 | 744 | I and II | 90 (LR) |
30 | < 50 | 726 | I and II | ND |
23 | 5,840 | 655 | I | 11 (LR) |
30 | < 50 | 602 | I and II | 97 (LR) |
17 | 90,800 | 580 | I and II | 51 (HR) |
42 | < 50 | 521 | I | ND |
44 | < 50 | 506 | I | 66 (HR) |
50 | 400 | 503 | I and II | 16 (HR) |
35 | < 50 | 485 | I | 16 (HR) |
27 | < 50 | 481 | I and II | 51 (HR) |
37 | < 50 | 410 | IV | 51 (HR) |
42 | < 50 | 405 | I | 11 (LR) |
60 | 57 | 388 | I | 58 (HR) |
29 | < 50 | 380 | I and II | 70 (LR) |
31 | 4,940 | 364 | I and II | ND |
Group II3 | ||||
35 | < 50 | 317 | I and II | ND |
35 | < 50 | 294 | IV | ND |
24 | 1,170 | 282 | I and II | ND |
30 | < 50 | 280 | III | 54 (LR) |
42 | < 50 | 258 | I and II | 102 (LR) |
49 | < 50 | 255 | I and II | 6 (LR) |
35 | < 50 | 208 | I | 84 (LR) |
32 | 369 | 180 | I | 51(HR) |
36 | 13,900 | 175 | I and II | 51 (HR) |
37 | < 50 | 161 | III | 81 (LR) |
28 | 67 | 160 | I and II | ND |
24 | 74,620 | 146 | I and II | ND |
51 | < 50 | 132 | III | 51 (HR) |
37 | 73 | 127 | IV | 81 (LR) |
48 | 5560 | 104 | I and II | 6 (LR) |
43 | < 50 | 103 | I and II | 86 (LR) |
37 | ND | 102 | I | 56 (HR) |
31 | < 50 | 76 | III | 52 (HR) |
23 | > 100,000 | 70 | I and II | 6 (LR) |
34 | 822 | 65 | III | 58 (HR) |
63 | 451 | 63 | I and II | ND |
44 | 5,140 | 60 | I and II | 51 (HR) |
25 | 95200 | 30 | I and II | 81 (LR) |
41 | ND | 22 | III | 33(HR) |
31 | > 100,000 | 16 | I and II | 70 (LR) |